stockrowCerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.
- Revenue
- −70.4%
- EPS
- −311.3%
- Free cash flow
- −31.5%
Quarter to June 2026, against a year earlier
Follow CNSY
Alert me
Cerenome, Inc. (CNSY) Altman Z-score
Cerenome, Inc.'s Altman Z-score for fiscal 2025 is −44.86, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −44.86 | 67.29 |
| FY2024 | −112.16 | (49.82) |
| FY2023 | −62.34 | (32.73) |
| FY2022 | −29.60 | 23.02 |
| FY2020 | −52.62 | (27.06) |
| FY2019 | −25.57 | 0.09 |
| FY2018 | −25.65 | (5.68) |
| FY2017 | −19.97 | (8,292.52) |
| FY2016 | 8272.54 | (109,765.58) |
| FY2015 | 118038.12 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.17 | — | 0.21 | |
| Retained earnings / total assets | (31.60) | — | −44.24 | |
| EBIT / total assets | (0.94) | — | −3.09 | |
| Market value of equity / total liabilities | 3.23 | — | 1.94 | |
| Sales / total assets | 0.32 | — | 0.32 | |
| Altman Z-score | Distress zone | −44.86 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −107.82 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CDIO Cardio Diagnostics Holdings, Inc. compare | −3.6× |
| IMNN Imunon, Inc. compare | −12.5× |
| SNTI Senti Biosciences, Inc. compare | −13.7× |
| PULM Pulmatrix, Inc. compare | −27.9× |
| CANF Can-Fite Biopharma Ltd compare | −28.0× |
| CNSY Cerenome, Inc. | −44.9× |
| PCSA Heatwurx Inc. compare | −251× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets